HMMR and ovarian carcinoma: In ovarian cancer, HMMR-AS1 was significantly upregulated in tumor tissues compared to normal tissues, which was related to advanced stages and lymphatic metastasis with a shorter overall survival time (p = 0.0075), and progression-free survival time (p = 0.0013) than those with lower HMMR-AS1 expression [51].